The WinRho.com requires both Adobe Flash Player 8+ and javascript enabled.
Please ensure your browser has javascript enabled and the Flash Player plugin installed.
ITP Education Kit
Learn more about ITP and WinRho® when you order the ITP Educational Resource Kit
ITP Juego Educativo
Aprenda más acercade ITPy WinRho® cuando usted ordena el ITP Juego Educativo de Recurso
Welcome to WinRho.com
Welcome to WinRho.com
This website has been a resource for people seeking information about ITP and WinRho® SDF for 5 years. WinRho® is a first-line treatment option for Immune Thrombocytopenic Purpura (ITP) that may be helpful for you.
Baxter's commitment to hematologic therapy continues with WinRho® SDF - the first Anti-D immunoglobulin treatment for Immune Thrombocytopenic Purpura or ITP for children and adults.
In a study of adults and children with chronic ITP, WinRho® demonstrates efficacy and duration of response — almost 90 days per treatment for adults and almost 37 days per treatment for children. The infusion time for WinRho® is only 3 to 5 minutes.1,2 A short infusion time could reduce the time you spend in your physician's office.
WinRho® SDF Liquid is Bioequivalent to WinRho® SDF Lyophilized1
In two comparative pharmacokinetics studies, 101 volunteers were administered the liquid or lyophilized formulation of WinRho® SDF intravenously (N=41) or intramuscularly (N=60). The formulations were bioequivalent following IV administration based on area under the curve to 84 days and had comparable pharmacokinetics following IM administration. The average peak concentrations (Cmax) of anti-Rho(D) for both formulations were comparable following IV or IM administration and occurred within 30 minutes or 2-4 days of administration, respectively. Both formulations also had similar elimination half-lives (t½) following IV or IM administration.
Indications and Usage1
WinRho® SDF must be administered via the intravenous route when used in clinical situations requiring an increase in platelet count to prevent excessive hemorrhage in the treatment of non-splenectomized, Rho(D) positive:
- children with chronic or acute ITP,
- adults with chronic ITP, or
- children and adults with ITP secondary to HIV infection
The safety and efficacy of WinRho® have not been evaluated in clinical
trials for patients with non-ITP causes of thrombocytopenia or in previously
splenectomized patients or in patients who are Rho(D) negative.
WinRho® SDF should not be administered to:
- Rho(D) negative patients
- splenectomized patients
Please review the Full Prescribing Information and Important Risk Information.
- WinRho® SDF [Rho(D) Immune Globulin Intravenous (Human)] package insert, Cangene Corporation,Winnipeg, Canada. Baxter Healthcare Corporation, Westlake Village, CA, USA, April 2006.
- Data on file, Cangene Corporation, Baxter Healthcare Corporation.
